Literature DB >> 18381641

Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.

Ana Gabrea1, Maria Luisa Martelli, Ying Qi, Anna Roschke, Bart Barlogie, John D Shaughnessy, Jeffrey R Sawyer, W Michael Kuehl.   

Abstract

The pathogenesis of multiple myeloma (MM) is thought to involve at least two pathways, which generate hyperdiploid (HRD) or nonhyperdiploid (NHRD) tumors, respectively. Apart from chromosome content, the two pathways are distinguished by five primary immunoglobulin heavy chain (IGH) rearrangements (4p16, FGFR3, and MMSET; 6p21, CCND3; 11q13, CCND1; 16q23, MAF; 20q12, MAFB) that are present mainly in NHRD tumors. To determine the prevalence and structures of IGH, immunoglobulin (IG) light chain, and MYC genomic rearrangements in MM, we have done comprehensive metaphase fluorescent in situ hybridization analyses on 48 advanced MM tumors and 47 MM cell lines. As expected, the prevalence of the five primary IGH rearrangements was nearly 70% in NHRD tumors, but only 12% in HRD tumors. However, IGH rearrangements not involving one of the five primary partners, and IG light chain rearrangements, have a similar prevalence in HRD and NHRD tumors. In addition, MYC rearrangements, which are thought to be late progression events that sometimes do not involve an IG heavy or light chain locus, also have a similar prevalence in HRD and NHRD tumors. In contrast to the primary IGH rearrangements, which usually are simple balanced translocations, these other IG rearrangements usually have complex structures, as previously described for MYC rearrangements in MM. We conclude that IG light chain and MYC rearrangements, as well as secondary IGH rearrangements, make similar contributions to the progression of both HRD and NHRD MM tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381641      PMCID: PMC3678755          DOI: 10.1002/gcc.20563

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  27 in total

Review 1.  Multiple myeloma: evolving genetic events and host interactions.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

2.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Authors:  Hervé Avet-Loiseau; Thierry Facon; Bernard Grosbois; Florence Magrangeas; Marie-José Rapp; Jean-Luc Harousseau; Stéphane Minvielle; Régis Bataille
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

Review 3.  Chromosome translocations in multiple myeloma.

Authors:  P L Bergsagel; W M Kuehl
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

4.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

5.  Genomic abnormalities in monoclonal gammopathy of undetermined significance.

Authors:  Rafael Fonseca; Richard J Bailey; Gregory J Ahmann; S Vincent Rajkumar; James D Hoyer; John A Lust; Robert A Kyle; Morie A Gertz; Philip R Greipp; Gordon W Dewald
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

6.  Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.

Authors:  Nicole Véronique Smadja; Dominique Leroux; Jean Soulier; Sylvie Dumont; Catherine Arnould; Sylvie Taviaux; Jean Louis Taillemite; Christian Bastard
Journal:  Genes Chromosomes Cancer       Date:  2003-11       Impact factor: 5.006

7.  Non-random chromosomal aberrations associated with multiple myeloma.

Authors:  J P Lewis; M R MacKenzie
Journal:  Hematol Oncol       Date:  1984 Oct-Dec       Impact factor: 5.271

8.  Characterization of MYC translocations in multiple myeloma cell lines.

Authors:  Amel Dib; Ana Gabrea; Oleg K Glebov; P Leif Bergsagel; W Michael Kuehl
Journal:  J Natl Cancer Inst Monogr       Date:  2008

9.  The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.

Authors:  Rafael Fonseca; Carina S Debes-Marun; Elisa B Picken; Gordon W Dewald; Sandra C Bryant; Jerry M Winkler; Emily Blood; Martin M Oken; Rafael Santana-Dávila; Natalia González-Paz; Robert A Kyle; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Philip R Greipp
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  32 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Authors:  John K Simmons; Aleksandra M Michalowski; Benjamin J Gamache; Wendy DuBois; Jyoti Patel; Ke Zhang; Joy Gary; Shuling Zhang; Snehal Gaikwad; Daniel Connors; Nicholas Watson; Elena Leon; Jin-Qiu Chen; W Michael Kuehl; Maxwell P Lee; Adriana Zingone; Ola Landgren; Peter Ordentlich; Jing Huang; Beverly A Mock
Journal:  Mol Cancer Ther       Date:  2017-05-18       Impact factor: 6.261

Review 3.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 4.  Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Authors:  Adriana Zingone; W Michael Kuehl
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

5.  Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.

Authors:  Gina Y Kim; Ana Gabrea; Yulia N Demchenko; Leif Bergsagel; Anna V Roschke; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

6.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Authors:  J R Sawyer; E Tian; J D Shaughnessy; J Epstein; C M Swanson; C Stangeby; C L Hale; L Parr; M Lynn; G Sammartino; J L Lukacs; C Stein; C Bailey; M Zangari; F E Davies; F Van Rhee; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

Review 7.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

8.  TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Authors:  John K Simmons; Jyoti Patel; Aleksandra Michalowski; Shuling Zhang; Bih-Rong Wei; Patrick Sullivan; Ben Gamache; Kenneth Felsenstein; W Michael Kuehl; R Mark Simpson; Adriana Zingone; Ola Landgren; Beverly A Mock
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

Review 9.  The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.

Authors:  Madhu P Menon; Stefania Pittaluga; Elaine S Jaffe
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

10.  OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.

Authors:  Thea Kristin Våtsveen; Erming Tian; Stine H Kresse; Leonardo A Meza-Zepeda; Ana Gabrea; Oleg Glebov; Hong Yan Dai; Anders Sundan; W Michael Kuehl; Magne Børset
Journal:  Leuk Res       Date:  2009-04-23       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.